APR 2 8 2008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Daren L. Stewart et al.

Application No.: 10/683,885

Filed: October 10, 2003

For: APPLICATOR FOR RADIATION

TREATMENT OF A CAVITY

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313 Examiner: John P. Lacyk

Group Art Unit: 3735

File No: 667P

Tiburon, California

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE, ON THE DATE INDICATED BELOW, AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313

-22-

DATE OF DEPOSIT APRIL 22, 2008

THOMAS M. FRELBURGEN, REG. NO. 27,063

SIGNED

DATE

DECLARATION UNDER 37 CFR 1.131

This is a declaration to show the inventors' prior conception of the invention before the effective filing date of Lubock Patents Nos. 6,955,641 and 6,923,754, coupled with diligence in continued work on the invention through filing of this application October 10, 2003. The effective filing date of both patents apparently is November 6, 2002.

Daren L. Stewart, Paul A. Lovoi, Thomas W. Rusch, Alex Lim and Darius Francescatti declare and state as follows:

1. We are the inventors in this application, as listed in the declaration as filed.

We conceived the invention of the claims under 2. consideration, claims 41-50 and claims 53-137, prior to the effective filing date of Lubock Patents Nos. 6,923,754 and 6,955,641, that is, prior to November 6, 2002. We were diligent toward developing this invention and toward reducing it to practice from a time prior to November 6, 2002 until the filing of the current patent application on October 10, 2003. We worked continually on all the many aspects of the applicator project. We were under pressure from our CEO and our company's investors to complete the balloon applicator, x-ray tube, controller and other components of the brachytherapy system to be launched and The balloon applicator itself included a number of different aspects, drainage being one of them. Ongoing work toward reducing the applicator to practice included many nondrainage aspects which had to be resolved before all of these features could be integrated into an applicator that could be built and tested. Two of the inventors were assigned to work on the applicator for more than a year. All aspects had to be addressed to arrive at a final design because some features would have an effect on others. All balloon applicator development from prior to 11/6/02 until the filing of our patent application included the concept of drainage, considered and then firmly incorporated, including the concept of suction holes in the applicator shaft to withdraw fluids near the balloon, and the

applicator in the system as ultimately launched and marketed has this feature.

- 3. An entry in the notebook of Thomas Rusch, 10/7/02, attached hereto as Exhibit A, regarding a brachytherapy applicator which is the subject of this patent application, states: "Consider having a drain port/membrane on our applicator and catheters, if necessary, to remove seroma. Use a std. squeeze bottle to apply suction force." The entry was made 10/7/02 to memorialize a discussion at a meeting with D. Francescatti and others 10/6/02. Though not the first conception of the invention of a balloon applicator with provision for drainage from the space between the balloon and the tissue of the cavity wall, this entry shows we were considering this improvement at least as early as 10/6/02.
- 4. Exhibit B is entitled "Xoft microTube Breast
 Brachytherapy System Preliminary Marketing Requirement
 Specifications", dated 11/12/02. The document outlines
 specifications of the system including the applicator and its
 shaft and balloon and relates to launch of the applicator
 project.
 - 5. A further entry in the notebook of Mr. Rusch, attached

here as Exhibit C, is dated 11/15/02. This entry discusses balloon behavior for a balloon applicator, and says questions the impact on dose of a contrast medium in the balloon.

- 6. Exhibit D is an unsigned version of a confidential disclosure agreement, in preparation for signatures, dated 11/27/02 between Xoft microTube, the assignee herein, and Polyzen, Inc., for the purpose of discussions on applicator design.
- 7. Exhibit E, 12/3/02, from the laboratory notebook of Paul A. Lovoi, discusses balloon information of Proxima and other brachytherapy balloon applicators. Includes notes on balloon design, shaft design and wound management, external and internal. Includes notes on processes for making brachytherapy balloons. A note at the bottom says "1/2 psi will stop fluid flow." This refers to small lumens in the applicator shaft for draining seroma, and overcoming the effects of surface tension in the small lumens. These were notes taken during a telephone conversation with a vendor. This was part of ongoing work on brachytherapy balloon applicator design.
- 8. Exhibit F, one page from internal PowerPoint presentation last updated 12/16/02. Entitled "Apollo Therapy

System" (with date October 2002), sheet schematic block diagram showing brachytherapy system, with applicator, x-ray source, controller, etc.

- 9. Exhibit G is another page from the same PowerPoint presentation (last updated 12/16/02) entitled "Needed Disclosures System". This page outlines the different aspects of the brachytherapy radiation system being developed by Xoft microTube including the applicator which was to have seroma drainage and vacuum conformity of tissue.
- 10. Exhibit H, 2/6/03, three pages, laboratory notebook of Daren Stewart, pages 41-43, refers to the balloon applicator project. The notes outline aspects of the applicator project and list "Jackson Pratt Drainage device" as a kit component (p. 41). Page 42 further describes the Jackson Pratt drainage device, an off the shelf component, saying it must "mate to the J-P port on the applicator."
- 11. Exhibit I, 2/7/03 (date halfway down page), entry in notebook of Steve Hansen, non-inventor employee of assignee involved in management of project. Notes of a staff meeting for planning on this project. Includes notes of telephone conference with D. Francescatti, with Daren Stewart, Alex Lim, Steve Hansen

and Tom Rusch present. Says "Idea of Dr. Francescatti — 6 to 8 feeder tubes that feed a main drain lumen. This will drain fluid & pull tissue to the applicator." The notes further state "Use JP [Jackson-Pratt] bulb attached during treatment." This shows the intention of the inventors to include the feature of drainage and suction in the applicator, and shows continuing work on this aspect, so that suction applied to the applicator will drain fluid and pull the cavity tissue to the applicator.

Exhibit J, 2/18/03, two pages, notebook of Daren 12. Stewart, pages 45 and 46, includes notes of Daren Stewart regarding a meeting with Alex Lim, Tom Rusch, Steve Hansen and Horst Adam concerning a 2/7/03 telephone call with Darius Francescatti. The notes discuss seroma drains for breast surgery. Further, the notes on "follow up from phone call on 2/7/03 with Darius Francescatti" discuss the drainage feature in the applicator, and several internal meetings that were held after the telephone conference with Dr. Francescatti. The notes confirm agreement "that a substantial effort needs to be made to include a drainage system in the applicator to remove fluid for patients who experience extreme buildup as well as prior to a treatment dose", and also notes "This item to be included in any future patent disclosures."

- 13. Exhibit K, 2/24/03, two pages of Stewart notebook, relating to design of applicator with balloon. Notes mention two port hub and center port to be used for drainage. Following page, also 2/24/03 ("MDM recap") says "Talk to Steve re: ports on inflation & suction (Need to be different)").
- 14. Daren Stewart notebook pages 26-27, Exhibit L, dated 3/21/03, discussing design of applicators, contrast medium in balloon, sourcing of balloons, shape and skin thickness of balloon, indicating continued work on balloon and balloon applicator.
- 15. Exhibit M, 3/26/03, Daren Stewart notebook entry, "Xoft Controller: Notes to self", discussing balloon shape and correlation of balloon shape with patient need, showing continued work on balloon and applicator.
- 16. Exhibit N, 4/2/03, Daren Stewart notebook entries, page 33 regarding different aspects of entire system to be constructed and marketed, including the controller or console and the applicator. Correlating correct applicator to patient.
- 17. Exhibit O, 4/30/03, Daren Stewart notebook entry regarding balloon design, mentioning ribs inside the balloon that

could potentially control the shape of the balloon. Shows continued work on balloon design, all aspects of which had to be designed and resolved prior to building and releasing the system.

- 18. Daren Stewart notebook, Exhibit P, three pages, entries dated 5/14/03 and 5/15/03, mentions "balloons with barium", goal of animal testing, other aspects of applicator in balloon design.
- 19. Exhibit Q, Stewart notebook dated 5/28/03, "Post Dry Run Animal Study Download". Mentions barium loaded balloons, and radio opaque markers on balloon, relative to balloon design, showing continued work on balloon design.
- 20. Exhibit R, 6/12/03 entry in Stewart notebook on balloon applicators, and x-ray imaging trials with balloons having contrast medium.
- 21. Exhibit S, 6/17/03, Daren Stewart notebook entry.

 "Meeting with Robert Bley". Mentions balloon and drainage in context of balloon design. Mentions Accusil, a balloon manufacturer.
- 22. Exhibit T, 6/18/03 entry in Stewart notebook, two pages, regarding final design of applicator and other components

of system to be produced. Mentions details of the hub of the applicator and balloon sizes, balloon stiffener. Second page of this two page exhibit mentions drainage; drain.

- 23. Exhibit U, 7/8/03 entry in Stewart notebook, concerning design of balloon, specifically balloon shapes and sizes to be made available.
- 24. Exhibit V, 7/9/03 entry in Stewart notebook "Applicator to do items". Mentions balloon drawings, "more shapes"; contrast info, tests; schedule for molded parts from Accusil; notes of phone call with Accusil regarding balloons with ribs and variable thickness.
- 25. Exhibit W, 7/16/03 entry in Stewart notebook, "meeting w/ Stellartech" list of matters to address regarding design of applicator, and mentions testing with all different sizes of balloons.
- 26. Exhibit X, engineering drawing dated 7/17/03 and shown as produced by Alex Lim. The drawing, numbered 710002, shows the applicator with a hub at the proximal end including three ports, one being a drainage port. A deflated balloon is shown at the distal end, and drainage ports are indicated in the applicator

shaft, seven drain holes at each of distal and proximal positions relative to the balloon.

- 27. Exhibit Y, engineering drawing showing applicator, without legend. This drawing, which we believe was produced at the same time or within a few days of Exhibit X, and similar to Exhibit X, shows the same applicator with the two sets of drain holes on the shaft distal and proximal of the balloon, but in this case with the balloon inflated.
- 28. Exhibit Z, 7/22/03, "Applicator Brainstorming Meeting" agenda prepared for meeting attended by inventors Paul Lovoi, Daren Stewart, Alex Lim and others. Typed agenda notes "Applicator with Drain/current design/textured balloon/multiple ports". Mentions other aspects of applicator design including balloon expansion limiter for size control. This copy has handwritten notes.
- 29. Exhibit AA, 7/22/03 entry in Daren Stewart notebook, "Applicator Patent Submission Mtg.", notes on the 7/22/03 meeting outlined above and indicating a list of features of the applicator was to be generated for the preparation of a patent application.

- 30. Exhibit AB, 7/25/03 entry in Stewart notebook, again relating to applicator balloon sizes, and with table of volumes versus dimensions.
- 31. Exhibit AC, 8/13/03 entry in Daren Stewart notebook, page 67, describing plan for animal testing with multiple shaped balloons, eight animals, and noting human studies to follow.
- 32. Exhibit AD, 8/14/03 entries in Stewart notebook, two pages, pages 68-69, "Animal Study #3 Preparation Meeting" further planning for animal testing/studies using balloon applicator designed pursuant to invention, with notes on scheduling, applicator parts to be ordered from Accusil, sizes of balloons and preferred barium.
- 33. Exhibit AE, 8/29/03 and 9/3/03 entries in Daren Stewart notebook, "Balloon Applicator Hazard Analysis", two pages (pp. 76-77). Explores different types of hazard, failure or problems that could occur with balloon and relates to balloon design, instructions for use.
- 34. Exhibit AF, 9/8/03 entry in Stewart notebook, p. 81, "Accusil agenda". Has notes on shaft thickness, balloon sizes and thickness of material, inflation valve for balloon, and other

issues to be raised with Accusil, the balloon maker. Shows ongoing work on improving the applicator.

- 35. Exhibit AG, 9/10/03, 9/11/03 and 9/12/03 entries, entitled "1st Day Goat #3", "Back @ Lychron", and "Lychron (animal testing laboratory), in Stewart notebook, three pages. Notes describe procedures used on goat, size of balloon and liquid filled into balloon, and results observed.
- 36. In September 2003 we had communications with our attorney, Thomas M. Freiburger, for preparation of a patent application on the applicator with its various innovative features. We received a first draft of the application from the attorney in about mid-September. On 9/22/03 we received a fax from the attorney, with an updated draft of the patent application, which was primarily the same as the application as filed.
- 37. The patent application was filed on October 10, 2003. Signatures on the declaration were provided later.

We further declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: 4/22/08	Daren L. Stewart
Date: 4/22/58	Paul A. Lovoi
Date: 4/22/08	Thomas W. Rusch
Date: 4/22/08	Alex Lim
Date:	Darius Francescatti

We further declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date:	Daren L. Stewart
Date:	Paul A. Lovoi
Date:	Thomas W. Rusch
Date:	Alex LAm
Date: 22 Apr 08	Darius Francescatti) '),)

```
12/07 Nijazi - SH, MF, TR -
       Thinks about manufacturability -
                                                  - school from home to manhet release
ch); M (36) 13/02 Vaic - 408-331-3124
                                                             Test embroller leckage - rang to 40kV.
                                                                                                                                                                                                                     - Bill will be there
                                                                      - Flant ing 100-200 ma an 10-th remider
                                                                                                                                                                                                                     - tomming
                                                      - Voltage between charges + earth, current between charges 4; earth
                                              The Medig
                                                      - Take p.s. to Bill tommen - upgrade to toky and determine reason for
                                                      - LID may be able to quie on hypertime molded another and in a little in
                                                                                                                                                                                           and the state of t
                                           10/2/02 Tube Meeting.
                                                   - Characterize blant would and meaner with current probe - Watel learning is proceeding - rother hampin / filaments twisting in 2-hole tuber.
                                                                                                        သည်။ မေသည် ကို သည် ကို သည် သည် ရှိသည် သည် ရှိသည် သည် သည် ကို မြို့ကြားမျိုးမျိုးသည်။
မေသများ သည်များသည် သည် သည် သည် သည် သည် သည် သည် မေသည် မေသည် မေသည် မေသည် သည်
                                                      Vince of the property of the state of the
                                                            · Sur has things to be demeloped
                                                         - Need HV singely and amount down under 50 auction, to do their med them interfered bound working. ( Need a filerest current source subject (from Bill P.) - 5W will amounted as file systems then data logging.
                                                             Hold on GUI work while we get more feelbeck from Michael.
 ( برسنگ
                                                         Critical gath - fil. suggling and HV suggling prototypes to test are - need HV relay to test areing +
                                                           Meeting will Lorraine Tafra, Danier Franchesette at Ken Blue - 10/1/12
                                          Darwi. Consider humg a draw port/ maken on our application and catheters, if necessary, to remove 5000Ms. Use a 5th square bottle to apply sneture force.

C. Rolling 2 22-07
```

Xoft microTube Breast Brachytherapy System Preliminary Marketing Requirement Specifications November 12, 2002

In-Vivo Device Position Check (QA): External imaging: Fluoroscopy, CT or ultrasound.

Target Tissue Depth: 1 cm at 100% Isodose Point.

Venues of Use: Unshielded Operating Room, Unshielded Treatment Room or Radiation

Oncology Suite.

Method of Application: Open cavity or percutaneous.

Fractionation Schedule: Single fraction IORT, single fraction percutaneous, post-pathological assessment or Multi-fraction (up to 10 fractions) delivered over up to 5 days post-pathological assessment.

Target Tissue Dose: Single fraction dose of 18 Gy; Multi-fraction dose of 34 Gy over 10 fractions (3.4 Gy/fraction).

Treatment Delivery Time: Single fraction IORT less than or equal to 30 minutes; Single fraction percutaneous, post-pathological assessment less than or equal to 45 minutes; Multi-fraction less than or equal to 10 minutes per fraction.

Surface to Target Ratio: Applicator surface to 1 cm treatment depth, less than 2.50.

Dose Homogeneity Index: Minimum of 0.70.

Maximum non-Conformability Post Installation: Total of 30% of candidates (5% of treated

tissue volume)

Maximum Tolerable Device Failure Rate: 10% for all reasons combined.

Edema/Drainage Management: Jackson-Pratt Complete Closed Wound Drainage System

Maximum Tumor Size: 2 cm

Minimum/Maximum Cavity Size: 4 cm; 5 cm Maximum Acceptable Trocar Size: 8 mm Device Shaft Outer Diameter: 6 mm, maximum

Device Shaft Length: 15 cm, maximum **Balloon Inflation Connector:** Luer fitting

Maximum Balloon Inflate/Deflate Time: 30 seconds

Patient Eligibility: >50 years of age, unifocal disease, N0, M0

Patient Ineligibility: Invasive or in-situ lobular carcinoma, DCIS, EIC, skin or chest wall

involvement, breast unsatisfactory for brachytherapy, last breast surgery more than 8 weeks prior

to planned brachytherapy.

Minimum Cup Size: B

Margin Status: Microscopically negative surgical margins >2 mm

Distance Edge of Cavity to Skin: 5 mm, minimum.

Product Conformability Range: 4-5 cm

Pre-Treatment Dose/Rate Measurement Capability Built in: Yes

Sterilization: One time sterile disposable.


Reusability: Disposable with provisions to prevent reuse, except for multi-fraction use in the

same patient.

Minimum Shelf Life: One Year.

Marketed Countries: US, Europe and Japan.

Average Selling Price: \$3,000 US. Cost of Goods: \$300/kit, maximum.



Between POLYZEN, INC., P.O. BOX 1487, Cary, NC 27512 And

XOFT MICROTUBE, 49000 Milmont Drive, Fremont, CA 95070

This agreement is made this 27th day of November, 2002, by and between Polyzen, Inc. and Xoft microTube.


- 1. <u>Purpose.</u> The parties wish to explore a business opportunity of mutual interest and in connection with this opportunity, each party may disclose to the other certain confidential technical and business information that the disclosing party desires the receiving party to treat as confidential.
- Each party (the Producing Party) may disclose to the other (the Recipient) certain trade secrets and confidential INFORMATION relating to specific design specification and fabrication of a certain specific device as listed below to Recipient in writing, tangible samples and/or orally in sufficient detail for Recipient to fully evaluate said disclosure:


Cathaters and Applicators for Brachytherapy

- 3. To be protected under the agreement, the term INFORMATION shall mean all business plans, information, data, facts, methods, projects, procedures and processes of manufacture, tooling and equipment, materials, compositions of matter, products and components of products, commercial information relating to suppliers, customers, marketing, sales, financial information, patent and trade secrets, proprietary know how and manufacturing process, research and development samples, management protocol, product designs, product development strategy, or such information which becomes known to Recipient as a result of access granted to Producing Party facilities, and which is disclosed to Recipient in tangible, documentary, or graphic form, and conspicuously labeled as confidential information of Producing Party. Oral disclosures for which protection is sought must at the onset be clearly identified as proprietary information and be documented in detail, labeled as above and submitted to Recipient in written and graphic form within (30) business days after disclosure.
 - 4. Recipient agrees that for a period of ten (10) years from the date of this agreement, he/she/ any agents and representatives will maintain in confidence the INFORMATION disclosed and will not use the INFORMATION for the ten (10) years period other than for evaluation purposes until or unless a formal written contract is entered into providing the terms and conditions of such use, all such information in tangible form and copies thereof shall be returned to producing party upon written request.
 - 5. The obligations of Recipient shall not extend to all or part of the INFORMATION:
 - (A) which is in the public domain or publicly known or available prior to the date of disclosure; or
 - (B) which can be demonstrated to have been in the possession of Recipient or affiliate(s) or available to Recipient or affiliate(s) from another source prior to disclosure; or

- (C) which becomes part of the public domain or publicly known or available prior to the date of publication or otherwise, not due to any unauthorized act or omission on the part of the Recipient or affiliate(s); or
- (D) which is rightfully received by Recipient from a third party without restriction of confidentiality thereof.
- 6. That Recipient agrees, except as otherwise expressly authorized by the Producing Party, not to make copies or duplicates of any confidential INFORMATION for a third party, other than those employee(s), agent(s), or affiliate(s) to whom information is necessary for evaluation purposes, or not to derive or attempt to derive, by reverse engineering, disassembling, decompiling, or otherwise, any portion of the confidential INFORMATION, which has not been previously disclosed by the Producing Party to Recipient. Recipient agrees for the benefit of the Producing Party to bind its employee(s), agent(s) and affiliate(s) receiving any INFORMATION for evaluation purposes, to observe confidentiality and restricted use obligations in respect of such INFORMATION, under terms no less stringent than those imposed by this Agreement on the Recipient.
- 7. Both parties agree that no right or license under any patent or trade secret now or hereafter owned or controlled by either party is granted to the other party by this agreement, nor is any such right or license to be implied from the disclosure by either party on its confidential INFORMATION to the other party except as expressly set forth herein.
- 8. Both parties agree that due to the unique nature of the confidential information there can be no adequate remedy at law for any breach of Recipient's obligations under these agreements, thereby resulting in irreparable harm to the Producing Party. Therefore, upon any such breach the Producing Party shall be entitled to appropriate mandatory or negative injunctive relief in addition to whatever remedies it might have at law.
- 9. The undersigned signatures represent that each has the actual authority to enter into the present agreement on behalf of his company.

Xoft microTube
By:
Name: Paul Lovoi
Title: President and CEO
Date: November 27, 2002
Polyzen, Inc.
By:
Name: Tilak M. Shah
Title: President
Date:





OFT Micro

Needed Disclosures - System

Interconnecting Sleeve

·Fittings for No Error Attachment

9

•Design Features that Minimize Straightening Errors and Friction

Applicator

·Seroma Drainage (C)

·Radio-opaque marking schema (C)

Vacuum conformity of tissue (C)

 Method for verifying distal positioning of x-ray catheter (C)

Control Console

• Software

• Dosimeters

·Position and use in arrays (NG)

Connection and cabling (NG)

Wireless operation (F)

Dual sensitivities per chip (NG)

•Use for re-verifying source location in multi-fraction (C)

Algorithms

·Mapping of cavity (NG)

·Mapping of cavity location (NG)


•Gap or seroma detection and location (to avoid repeated imaging)

Treatment optimization (NG)


Rotary treatment (F)

Real time treatment algorithms (F)

Xoft microTube Proprietary



Best Available Copy Interaction dependencies Disposable · Applicator 76.5 A small straight section his should & H down the applicator strodycer Sheath: The Theast. The applicator must Sit. I. D. of the sheath with with with the option to filled applicator ckson Pratt dramage of the shelf component. device It can This applica Balloon helf valves (Helkey ver 51ip top syringe devices Once ballon inflation l Catheter: The catheter 10 men must stide I clear ande between the sofficient clearanthe I.D. satheter and the I.D. provide





SAB Meeting Monning "What can be done by April 15th ? **EXHIBIT I** 29 JANG3 ~ (P meeting Zpm a Write Application Disclosure - Alex. OF FEBOS From with Dr. Francoski Dolen Staret, Alexa, Steath, Tan R Idea of Dr. Francisti Little application that feed a main discretion the application of the - Je J P bulbathache during treatment.

Seroma the consumbing of serum.

There has not been any clothing of no bland is present.

My experience — remade amont of seroma — 5 troops or more Proxima experience 87e503 Cather My.
HA, GROAL, TR, St. Deen Stuat.
O Do we need to provide a tricar.





2/24/03 XOFT Acusil Assembly Sterlepks Design option use a sheaff over X-Ra autheter for treatment the becomes disposable for every to eatment) Advantages s'arger suction luments s'easier (manufacturable device TFE for a Sheath 1001 tolorase Coextrude X-Ray catheter extrusion with something other than me that will give the "rigidity" decron Kevlar Siter type natorial 2/24/03 NIDM Jecap = Simtee (part al polymer. cation) Talk to Steve re: ports on I flator d'suction (Need to be different)

EXHIBIT L 3/21/03 Conf. call, Dr Marty Kersch delus with new applicatos. No human 1-2 week post op relation over tystill 790 dilution of contrast medium
M9x + themselves insert in an exam room. Ultrasound on plan 5.105 Silicone molds, with lesions, with confires Who was I that had then How much do they cost? How long willthe take to get? Do we need to sabricate our Make an objorg talloon on an extrision Do we have all the tools needed? Trocurs, sheatlas etc.

8 abrasive motory

. suture miles pal


. ribs


. charel tissue Ballow Station 12 check port, 5 kin thickness o ble have an advantage in ue can wipe down our catheter

3/26/03 Controller & Notes to self:
interactions with
cooling set etc. applicator, 1 ray catheten 300 i uns 6/day 01300 days 7 > Applicator I,D. Serialized? > Flow sensor? 3 Bar code reader imbed it in the poll back head? Application de terme de Dollows Elepo We need to verify or determine what application is in the patient? Datient Dy bar code on the Doctoge one sets still on hat then read by reade on console

EXHIBIT N Controlles (Console) my 3 Sec Tom's notes from last weeks into CSM norsing Rith Mc Cracker by one? Call Vonce IV pole? on Tom's astes screen that it correct · X-Ray Cathot

D. fo the source chip barade, etc.





of annal testing Corelin -> show a therapeutic dose in therapeutic time. what is required from me with balloon catheter - Hoop with starless steel an Ulfrasound of ? Inwhat configurations, Stanless top o Template ? What does it look we Dage






EXHIBIT Q 5/28/03 Post Dry Run Annal Study Download Radio opaque morter on ballon

Sall Accusen & See of the marking

metarials +> Barn loaded balloon



, 4 1 1 EXHIBIT S 48 Meeting with Robert Bley · balloons · review phots a C-An-maire SAB & animal stroly 2020 by everyth fantalung 12 RTV discussed printing (silt screening)
balloon
docinege







EXHIBIT U Balloon shapes bith a 4 et 5 cm. spherical
balloon shape. & Measure out the Manusosote device new design / de signs 485 cm 3 8 4 cm 586 cm . Spherical Sana balloan Sphereal (same ballow) (Same balloon 4 dia 6 length ellipsoidal Contrast Shares do abeling



1 1 1 1 58 EXHIBIT W Meeting w/ Stellartech For X-Ray cathefor Send sean all part duys.


5 Hub Capplicator

I sent duy, Hb Revol 4 71004.1.3 us convister Dag design

Spike into author bag


Connect with Iverth

To buch tibry. order Mc Master parts > girct release > 4,6 mg (dual in house on console Aurmal Study ready prototypes Testing of the all different 5,72es



12

EXHIBIT Y



Applicator Brainstorming Meeting 7/22/2003

Appl	icator with Drain
	Current design
	Textured balloon
	Multiple ports

ta disclose more

Applicator connectors

Unique interaction with insertion tool

Balloon with variable wall thickness to control shape

Multiple balloons for shape

Balloons with ribs for shape

Puncture resistant balloons

Bioerrodiable balloon

Contrast material built into wall

• Contrast material in channels or volumes using multiple balloons Applicator with coatings

For aiding removal

To aid insertion of source

To reduce adhession

To aid wound healing

Applicator shaft with depth markers

• Wound management with seal

With drug delivery for wound healing

Applicator with radiation adsorber to tailor dose Applicator with radiation adsorber to tailor dose

Applicator with ability to translate source. > X Roy at the can move independent (Applicator with high compliance)

Applicator with high compliance

Meshbaskets

Made from Nitinol

Made for Bioerrodiable material

Expansion control for basket – one size fits all

Contrast

Using contrast to image and then removing for treatment


Using contrast with balloon cavity thickness to tailor radiation dose


Stiffemer

Variable stiffness

Supporting balloon shape

Balloon expansion limiter for size control = Paul > ciggr band rdeer,








EXHIBIT AD 8/14/03 Thursday Annual Study # 3 Preparation Meets · disussion of GLP VS. non GLP get a copy of FDA submission downent a current treat week is Sept. 22-26 4 thongs need to get done li Applicator 4 sizes 3-4 b) 4-5 d) elliptica -> we are now talking about using a 3, 4,5, 6 sphere our data point. Dallons should have loading (370) we need to get a bag saler/pouch secler 2. System > power to tabe X-Ray Sources > findes




EXHIBIT AE Ballon Applicator Hazard An Infedior or fever

in non-stersle


riaction to material Device be come dislodged

- to alloon reptures

- fluid leaks oct of balloon


valve

- shaft gets libbe or fear stroma in center lumen to be corres de fached e sturd leak from dramage bobes mo Fxcess ve alternation force moen to User mixes up ports accidentally draws ballown,
NB marked or Pushes or prehes



1 1 1 EXHIBIT AF CeeW. cell 58)-692-0059 714) 993-4100

EXHIBIT AG 83 9/10 1st day goet # 3 Smaller breasts > slight sede from the gas I treat & image on back We are placing & 25% Barren Filled Dallood 4-5 cm. be Qa / HA 4-5 cm ballow Silled with 37cc + 2cc with contrast GIL: et; cal ballon has 100 ec nittizce contrast 4-5cm we removed 15 cc



Checked goat in morning. She was ale not playing with tibes. Entry Approx. 30 m. nutes 0 smg gas to ga her from standing into the treatment room. Warmth about the same as yesterday.
Tissue looks good. 37.7°C Discharge catheter. Make one or 2 catheters that we can use to discharge full energy @ the end of each treatment. If all works well, we could end up with 80 data points of worst case failure Images taken & stored Drang ballour de measure volume 39 ce removed from spherical 75 cc removed from elliptical For study: 16 stylets stersle